China's Voice Resonates in Baku

On May 21–22, 2026, the "Turkic World Cardio-Oncology Congress & the First International Summit on Artificial Intelligence and Robotic Cardiology," jointly hosted by the Ministry of Health of Azerbaijan, the National Oncology Center, and the Cardiology Research Institute, was grandly held in Baku, Azerbaijan. Orienter was honored to be invited to participate.

More than 300 experts from eleven countries—including China, Germany, Azerbaijan, and Turkey—gathered to explore the frontiers of cardio-oncology and discuss the medical applications of precision medicine, robotic surgery, and artificial intelligence.

Participants engaged in in-depth exchanges on topics such as the management of cardio-oncological comorbidities, AI-assisted diagnosis, interventional robotics, and precision testing in emergency care. Discussions focused on optimizing diagnostic and treatment protocols for cancer patients with cardiac complications, expanding the application of minimally invasive robotic cardiac surgery, and leveraging machine learning for imaging analysis and cardiac risk prediction—advancing early-stage and personalized diagnosis and treatment.

China's Voice, National Strength

As the only Chinese company invited to deliver a keynote speech in the main venue, Orienter took center stage. Mr. Li Yiguang delivered an in-depth presentation titled "Reshaping the Emergency Testing Ecosystem: Integrated Cardiac Biomarker and Cytokine Profiling for Precision Cardiovascular Disease Management," drawing significant attention and enthusiastic responses from the audience.

During the presentation, Mr. Li Yiguang provided a detailed introduction to Orienter's self-developed, full-process "from sampling to disposal" TLA system. This innovative solution integrates the entire workflow—sample collection, automated transmission, precision testing, intelligent review, post-processing, and waste archiving—creating a complete intelligent closed loop.

Furthermore, leveraging its independently developed chemiluminescence technology platform, Orienter enables multiplex cytokine testing, providing reliable and robust data support for clinical screening, disease assessment, and precision diagnosis and treatment of cardiovascular diseases, tumors, and various inflammatory conditions.

This international academic appearance represents strong industry recognition of Orienter's core technologies and innovative achievements. Looking ahead, Orienter will continue to deepen its commitment to innovation and R&D in the in vitro diagnostics (IVD) field, strengthen international academic exchange and collaboration, and consistently deliver high-quality Chinese IVD innovations. The company remains dedicated to empowering global healthcare and advancing the continuous upgrade of precision diagnosis and treatment worldwide.